Pipeline: New therapies to come for debilitating eye diseases
New drug from Gensight Biologics hits pipeline
GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.
Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.
Related: Myopia control data and whats to come with Dr. Noel Brennan
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Recent Videos
Related Content
